A Data Resource for Analyzing Blood and Marrow Transplants

国际血液和骨髓移植研究中心(CIBMTR)为临床研究 致力于解决造血细胞移植(HCT)中的重要问题的计划 为科学界提供独特的数据和统计专业知识资源。CIBMTR包括&gt；400 共享HCT结果数据的HCT中心和维护临床数据库的统计中心 有超过250,000名接受HCT的人的信息。这些数据和可用的分析支持 通过CIBMTR统计中心，成功完成了数百项研究。 CA76518为这些活动提供主要支持。此应用程序请求为下一个5年提供资金 多年来支持这一资源，以便为生物医学界提供持续获取高 高质量的临床数据库和统计支持，以促进临床研究。计划资源 改进措施包括开发电子数据获取技术，以便利 广泛的美国和非美国HCT中心；与其他国内和国际合作 组织增加可用于研究罕见适应症和新的HCT移植的数据 技术；收集有关造血干细胞其他治疗应用结果的数据； 扩大关于晚期效应和长期生活质量的数据；开发新的生物统计方法以 应对在分析HCT结果方面的挑战、需求和机遇。CIBMTR致力于 满足快速发展领域中调查人员的需求。它已经并将在基础设施的基础上建设 通过U24-CA76518的支持和与其他人的合作伙伴关系来更好地服务于研究社区。 本供资周期和以前供资周期内的活动不仅产生了许多关于重要问题的出版物 HCT中的问题，但也为极大地扩大全球数据合作创造了机会 交流和观察性HCT研究，对美国多中心的成功做出了重大贡献 HCT的临床试验网络。已经在进行中并计划在下一个供资周期进行的改进将 允许更深入地探讨HCT和HCT后生活质量的免疫生物学方面。总而言之， CIBMTR在U24-CA76518的支持下，继续在促进 HCT的临床研究。

The Center for International Blood and Marrow Transplant Research (CIBMTR) is a clinical research program dedicated to addressing important issues in hematopoietic cell transplantation (HCT) by offering a unique resource of data and statistical expertise to the scientific community. The CIBMTR includes > 400 HCT centers that share data on HCT outcomes and a Statistical Center that maintains a clinical database with information for more than 250,000 HCT recipients. These data and the analytic support available through the CIBMTR Statistical Center have led to successful completion of hundreds of studies.U24- CA76518 provides the primary support for these activities. This application requests funding for the next 5 years to support this resource in order to provide the biomedical community continued access to a high quality clinical database and statistical support to facilitate clinical research. Planned resource enhancements include development of electronic data acquisition technology to facilitate participation by a wide range of U.S.and non-U.S. HCT centers; collaboration with other domestic and international organizations to increase the data available to study transplantation for rare indications and new HCT technologies; collecting data on outcome of other therapeutic applications of hematopoietic stem cells; expanding data on late effects and long-term quality of life; and developing new biostatistical methodology to address the challenges, needs and opportunities in analyzing HCT outcomes. The CIBMTR is committed to meeting the needs of investigators in a rapidly evolving field. It has and will build on the infrastructure made possible by support from U24-CA76518 and partnership with others to better serve the research community. Activities during the current and previous funding cycles have led to not only many publications on important issues in HCT but also have created the opportunity for greatly expanded global collaboration in data exchange and observational HCT research and contributed substantially to the success of a U.S. multicenter clinical trials network in HCT. Enhancements already in progress and planned for the next funding cycle will allow more in-depth exploration of immunobiologic aspects of HCT and post-HCT QOL. In summary, the CIBMTR, with the support provided through U24-CA76518, continues to play a unique role in facilitating clinical research inHCT.